文献速递骨质疏松与代谢性骨病

白人与台湾绝经后女性口服伊班膦酸生物利用度的种族差异

Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.
PubMed 文献 · Osteoporos Int · 2019-10-23

两项1期研究共纳入35名白人和16名台湾绝经后女性,单次口服伊班膦酸150 mg后比较药代动力学;台湾女性AUC、Cmax及尿药回收率更高,表观清除率和表观分布容积更小,生物利用度似乎更高。

要点

  • 台湾绝经后女性口服伊班膦酸150 mg后AUC为白人的2.41倍。
  • 台湾女性Cmax和Ae%分别为白人的1.69倍和2.95倍。
  • 台湾女性CL/F和Vd/F分别为白人的1/2.48和1/2.46。

核心结论

  • 口服伊班膦酸150 mg后药代动力学存在种族差异,台湾女性生物利用度似乎高于白人女性。
  • 生物利用度差异似乎是导致CL/F和Vd/F种族差异的主要原因。

研究设计与样本

  • 两项独立的1期研究,共纳入35名白人和16名台湾绝经后女性,单次口服伊班膦酸150 mg。

主要发现

  • 台湾女性平均AUC为白人的2.41倍,平均Cmax为1.69倍,平均Ae%为2.95倍。
  • 台湾女性平均CL/F为白人的1/2.48,平均Vd/F为白人的1/2.46。
  • 两组平均CLr和半衰期无显著差异。
  • 多重线性回归分析显示,校正其他变量后种族影响药代动力学性质。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Following 150 mg of oral ibandronate, Taiwanese females have greater serum and urine levels of this drug and bone resorption marker suppression than Caucasian women. These inter-ethnic differences seems to be partly explained by a 2.48-fold higher bioavailability of ibandronate in Taiwanese postmenopausal women. INTRODUCTION: Interethnic differences in the pharmacokinetics of oral ibandronate for osteoporosis are unknown. We compared the disposition of oral ibandronate between Caucasian and Taiwanese postmenopausal women. METHODS: Ibandronate 150 mg was administered to 35 Caucasian and 16 Taiwanese postmenopausal women in two separate phase 1 studies. Interethnic comparisons were performed to assess pharmacokinetic properties, including the area under the concentration-time curve (AUC), peak concentration (Cmax), elimination half-life, urinary drug recovery (Ae%), renal clearance (CLr), apparent total clearance (CL/F), and apparent volume of distribution (Vd/F). RESULTS: The mean AUC, Cmax, and Ae% were 2.41-, 1.69-, and 2.95-fold greater in the Taiwanese than in the Caucasian subjects, and the average CL/F and Vd/F were 2.48- and 2.46-fold smaller. There were no significant differences in mean CLr and half-life between both groups. As bisphosphonates are not biotransformed but are mainly excreted in the urine, the total body clearance is close to the CLr. These results suggested a larger bioavailability in the Taiwanese group which resulted in the differences in the CL/F and Vd/F. Multiple linear regression analysis demonstrated ethnicity influences of the pharmacokinetic properties after adjusting for the other variables. CONCLUSIONS: Bioavailability was largely responsible for the interethnic pharmacokinetic differences following oral administration of 150 mg ibandronate and seemed greater in the Taiwanese compared with the Caucasian subjects. Further dose-ranging studies are warranted to determine the optimal dosages of oral ibandronate in patients of Asian or Taiwanese ethnicity.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chiu WY, Lin CJ, Yang WS, et al. Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporos Int. 2019. PMID: 31642977. doi:10.1007/s00198-019-05127-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。